SCHEMBL12303151

SCHEMBL12303151

Cc1cc(Nc2n[nH]c3ncccc23)nc(-c2ccccc2C(F)(F)F)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIP4K2C Q8TBX8 1/20 0.45
CYP1A2 P05177 12/20 0.44
CYP2C19 P33261 10/20 0.44
CYP3A4 P08684 10/20 0.44
CYP2D6 P10635 9/20 0.44
ALDH1A1 P00352 4/20 0.44
USP2 O75604 2/20 0.44
ALOX15 P16050 1/20 0.44
CASP1 P29466 1/20 0.44
CASP7 P55210 1/20 0.44
GLA P06280 1/20 0.43
TSHR P16473 5/20 0.42
CYP2C9 P11712 3/20 0.42
LMNA P02545 2/20 0.42
RECQL P46063 1/20 0.42
USP1 O94782 7/20 0.42
WDR48 Q8TAF3 7/20 0.42
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
HSD17B10 Q99714 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL961789 0.88 PIP4K2C (0.43) PIP4K2CCYP1A2CYP2C19CYP3A4CYP2D6
SCHEMBL12914219 0.87 PIP4K2C (0.47) PIP4K2CCYP1A2CYP2C19CYP3A4CYP2D6
SCHEMBL786723 0.86 CYP1A2 (0.45) CYP1A2CYP2C19CYP3A4CYP2D6ALDH1A1
SCHEMBL11917652 0.86 CYP1A2 (0.41) CYP1A2CYP2C19CYP3A4CYP2D6ALDH1A1
SCHEMBL958865 0.84 CYP1A2 (0.44) PIP4K2CCYP1A2CYP2C19CYP3A4CYP2D6
SCHEMBL961801 0.82 PIP4K2C (0.43) PIP4K2CCYP1A2CYP2C19CYP3A4CYP2D6
SCHEMBL957594 0.82 PIP4K2C (0.42) PIP4K2CCYP1A2CYP2C19CYP3A4CYP2D6
SCHEMBL958460 0.81 PIP4K2C (0.44) PIP4K2CCYP1A2CYP2C19CYP3A4CYP2D6
SCHEMBL959116 0.81 GSK3A (0.57) CYP1A2CYP2C19CYP3A4CYP2D6ALDH1A1
SCHEMBL962173 0.81 PIP4K2C (0.41) PIP4K2CCYP1A2CYP2C19CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110224197-A1 PYRIMIDINES AND PYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-09-15 US disclosed
US-20110224197-A1 PYRIMIDINES AND PYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-09-15 US disclosed
WO-2009145814-A9 PYRIMIDINES AND PYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-05-14 WO disclosed
WO-2009145814-A2 PYRIMIDINES AND PYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224197-A1 PYRIMIDINES AND PYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES GSK3B, CDK3, GSK3A PIP4K2C 854/4885CYP1A2 4411/4885CYP2C19 4462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.